Pharma Agnovartis Ag Novartis Net Worth

What's Pharma Novartis's mailing address?

Pharma's mailing address filed with the SEC is LICHTSTRASSE 35LICHTSTRASSE 35, , BASELBASEL, V8V8, 40564056.

Insiders trading at Poseida Therapeutics

Over the last 4 years, insiders at Poseida Therapeutics have traded over $7,666,974 worth of Poseida Therapeutics stock and bought 3,065,405 units worth $15,916,632 . The most active insiders traders include David Hirsch, Life Sciences Holdings Ltd ..., and Eric Ostertag. On average, Poseida Therapeutics executives and independent directors trade stock every 18 days with the average trade being worth of $303,665. The most recent stock trade was executed by Eric Ostertag on 8 August 2022, trading 142,857 units of PSTX stock currently worth $500,000.

What does Poseida Therapeutics do?

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Poseida Therapeutics executives and stock owners

Poseida Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Eric M. Ostertag,
  CEO & Director
• Dr. Eric M. Ostertag M.D., Ph.D.,
  Exec. Chairman
• Mark J. Gergen J.D.,
  CEO & Director
• Mark J. Gergen,
  Pres, Chief Bus. Officer & Director
• Harry J. Leonhardt,
  Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Brent Warner,
  Pres of Gene Therapy
• Harry J. Leonhardt Esq., J.D.,
  Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Lisa Portale,
  Sr. VP of Regulatory Affairs
• Dr. Matthew A. Spear,
  Chief Medical Officer
• Dr. Devon J. Shedlock Ph.D.,
  Chief Scientific Officer of Cell Therapies
• Sarah Thailing,
  Director of Corp. Communications & IR
• Kristin Martin,
  Chief People & Admin. Officer
• Kerry D. Ingalls,
  Chief Operating Officer
• Johanna M. Mylet CPA,
  Chief Financial Officer
• David Hirsch,
  Director
• Catherine J Mackey,
  Director
• John P. Schmid,
  
• Sean Murphy,
  Director
• Kristin Yarema,
  President and CEO
• Life Sciences Holdings Ltd ...,
  
• Pharma Agnovartis Ag Novartis,
  
• Rafael Amado,
  
• Matthew A. Spear,
  Chief Medical Officer
• Kerry D. Ingalls,
  Chief Operating Officer
• Harry J Leonhardt,
  GC & Chief Compliance Officer
• Brent Warner,
  President, Gene Therapy
• Luke Corning,
  
• Johanna Mylet,
  Chief Financial Officer
• Eric Ostertag,
  Director
• Mark J Gergen,
  Executive Chairman
• Life Sciences Holdings Ltd ...,
  10% owner
• Charles M Baum,
  
• Cynthia Collins,
  
• Marcea Bland Lloyd,
  
• Syed Ali Aamir Rizvi,
  Chief Medical Officer